These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8622064)

  • 1. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.
    Furman WL; Baker SD; Pratt CB; Rivera GK; Evans WE; Stewart CF
    J Clin Oncol; 1996 May; 14(5):1504-11. PubMed ID: 8622064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.
    Stewart CF; Baker SD; Heideman RL; Jones D; Crom WR; Pratt CB
    J Clin Oncol; 1994 Sep; 12(9):1946-54. PubMed ID: 8083716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
    Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
    J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of topotecan for pediatric patients with malignant solid tumors.
    Pratt CB; Stewart C; Santana VM; Bowman L; Furman W; Ochs J; Marina N; Kuttesch JF; Heideman R; Sandlund JT
    J Clin Oncol; 1994 Mar; 12(3):539-43. PubMed ID: 8120551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
    Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG
    Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
    Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study.
    Tubergen DG; Stewart CF; Pratt CB; Zamboni WC; Winick N; Santana VM; Dryer ZA; Kurtzberg J; Bell B; Grier H; Vietti TJ
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):352-61. PubMed ID: 8888741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the clinical pharmacology of topotecan.
    Dennis MJ; Beijnen JH; Grochow LB; van Warmerdam LJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-12-S5-18. PubMed ID: 9122737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.
    Creemers GJ; Gerrits CJ; Schellens JH; Planting AS; van der Burg ME; van Beurden VM; de Boer-Dennert M; Harteveld M; Loos W; Hudson I; Stoter G; Verweij J
    J Clin Oncol; 1996 Sep; 14(9):2540-5. PubMed ID: 8823333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, pharmacokinetic and biological studies of topotecan.
    O'Dwyer PJ; LaCreta FP; Haas NB; Halbherr T; Frucht H; Goosenberg E; Yao KS
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S46-52. PubMed ID: 8070027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Raphael B; Vinci RZ
    J Clin Oncol; 1994 Mar; 12(3):553-9. PubMed ID: 8120553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.
    Wall JG; Burris HA; Von Hoff DD; Rodriguez G; Kneuper-Hall R; Shaffer D; O'Rourke T; Brown T; Weiss G; Clark G
    Anticancer Drugs; 1992 Aug; 3(4):337-45. PubMed ID: 1330081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
    J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics of topotecan.
    Herben VM; ten Bokkel Huinink WW; Beijnen JH
    Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
    Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios MB; Plunkett W; Keating MJ
    Blood; 1993 Mar; 81(5):1146-51. PubMed ID: 8382970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
    Furman WL; Stewart CF; Kirstein M; Kepner JL; Bernstein ML; Kung F; Vietti TJ; Steuber CP; Becton DL; Baruchel S; Pratt C
    J Clin Oncol; 2002 Mar; 20(6):1617-24. PubMed ID: 11896112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.